: Although postnatal depression is now well recognized, there is also a risk of depressive symptoms during perimenopause. The mechanisms underlying perimenopausal depression are still poorly understood; however, there are available treatment options. : This review describes: the current pharmacotherapeutic approaches for perimenopausal depression, their strengths and weakness, and provides recommendations on how current treatment can be improved in the future. An electronic search identified specific guidelines for the treatment of perimenopausal depression released in 2018, as well as recent clinical studies on the subject. : The 2018 guidelines recommend selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) as front-line medications for perimenopausal depression, but SSRIs and SNRIs are not always effective. The efficacy of estrogen in perimenopausal depression is well documented, but estrogen is not FDA-approved to treat mood disturbances in perimenopausal women. Clinical practice guidelines currently recommend to restrict hormone therapy to the symptomatic treatment of menopause (not for the prevention of chronic diseases). Research with new estrogenic compounds is under way to improve their benefit/risk ratio in perimenopausal depression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14656566.2019.1645122 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mental Health Status Among Perimenopausal Women in Urban Slums: A Cross-Sectional Study.
Cureus
November 2024
Community Medicine, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, IND.
Background Menstruation is linked to psychological issues, particularly during its cessation. The premenopausal, perimenopausal, and postmenopausal stages of a woman's life are associated with a higher likelihood of mental health concerns. This study aims to assess the prevalence of stress, anxiety, and depression, as well as identify factors associated with these conditions among perimenopausal women living in urban slums.
View Article and Find Full Text PDFExploring heterogeneity of perimenopause with application of multivariable analysis approaches.
BMC Womens Health
December 2024
Gynecology Clinic, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510632, China.
Article Synopsis
- This study aimed to understand the varying symptoms of perimenopause by using advanced statistical methods to create a comprehensive assessment framework that combines multiple scales related to insomnia, anxiety, and depression.
- A clinical study in Guangzhou enrolled 336 perimenopausal patients, and a framework was developed to identify six factors affecting their experience, such as sleep disturbance and fatigue, validated through psychometric analysis.
- The findings suggested four distinct profiles of perimenopause symptoms, highlighting the complex and varied nature of the condition across different individuals.
Sociocultural and Clinical Determinants of Sexual Dysfunction in Perimenopausal Women with and Without Breast Cancer.
Curr Oncol
November 2024
Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
Breast cancer survivorship is a recognized risk factor for sexual dysfunction, with various clinical, sociocultural, and psychological factors potentially interacting differently across populations. This study compared sexual dysfunction, anxiety, and depression between females with breast cancer and those without, aiming to identify associated factors. A total of 362 females participated, including 227 with sexual dysfunction and 135 controls.
View Article and Find Full Text PDFEstradiol modulates resting-state connectivity in perimenopausal depression.
J Affect Disord
February 2025
Department of Psychology & Neuroscience, University of North Carolina, Chapel Hill, NC, United States of America.
The perimenopausal transition is marked by an increased risk for affective dysregulation and major depressive disorder (MDD), with hormone replacement therapy using estradiol (E2) showing promise for alleviating symptoms of perimenopausal-onset MDD (PO-MDD). Although E2's effectiveness is recognized, its mechanisms underlying mood symptom modulation remain to be fully elucidated. Building on previous research suggesting that E2 may influence mood by altering cortico-subcortical connectivity, this study investigated the effects of transdermal E2 on resting-state functional connectivity (rsFC) in perimenopausal women with and without PO-MDD, focusing on rsFC changes using seed regions within reward and emotion processing networks.
View Article and Find Full Text PDFBehavior, hormone, and gut microbiota change by YYNS intervention in an OVX mouse model.
Front Cell Infect Microbiol
November 2024
Department of Medicine, Hunan University of Chinese Medicine, Changsha, China.
Article Synopsis
- Perimenopause depression disorder (PDD) is common, characterized by depression and symptoms like hot flashes, linked to low estrogen levels, with emerging research tying it to the endocrine-brain-gut-microbiota axis.
- The study used a mouse model to simulate menopausal depression and tested the effects of a traditional Chinese remedy, Yangyin-ningshen formula (YYNS), alongside estrogen (E2) on behavioral and microbiome changes.
- Results indicated that YYNS significantly alleviated depression symptoms, improved microbial diversity, and altered hormone levels in the OVX mice after three weeks, suggesting its potential role in managing PDD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!